Nektar Reports on Advancements with Clinical Pipeline and Introduces New
Preclinical Candidates at Investor and Analyst R&D Day
SAN FRANCISCO, Oct. 8, 2013
SAN FRANCISCO, Oct. 8, 2013 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR)
will present an overview of the company's proprietary drug candidate pipeline
during the company's R&D Day for investors and analysts today from 11:30 a.m.
to 4:30 p.m. ET in New York City.
Pain management specialists will present data from two Phase 2 studies of
NKTR-181, the company's novel mu-opioid analgesic molecule. New topline
clinical data will be presented from an ongoing investigator-sponsored Phase 2
study of Nektar's proprietary cancer drug candidate, NKTR-102, in patients
with Avastin-resistant high-grade glioma. The company will also present new
receptor-based research for NKTR-192, the company's novel analgesic molecule
for acute pain, which is currently in Phase 1 development. Noted clinical
experts in the fields of pain and oncology will participate in two separate
panel discussions on current treatment practices and share their perspectives
on the medical need for new treatment options.
Also, for the first time, the company will provide details for two new drug
candidates including a peripherally-acting kappa agonist for visceral pain,
and a dual-receptor agonist/antagonist molecule for neuropathic pain, both of
which were created using the company's advanced polymer conjugate discovery
platform. In addition, new preclinical data will be discussed for NKTR-214,
Nektar's cancer immunotherapy candidate.
"Nektar has one of the most exciting and robust pipelines in the biotech
industry. In addition to our four partnered programs, which are in or have
completed Phase 3 studies, we have a deep proprietary pipeline of novel
therapeutic candidates," said Howard W. Robin, President and Chief Executive
Officer of Nektar Therapeutics. "Today's presentation showcases the innovation
and productivity of the Nektar research and development team."
The live webcast from will start at 11:30 a.m. ET and can be accessed by
visiting the investor relations section of Nektar's website at
http://www.nektar.com or by clicking on the following link:
http://ir.nektar.com/eventdetail.cfm?eventid=135267. To ensure a timely
connection to the webcast, it is recommended that users register 15 minutes
prior to the scheduled webcast. This webcast will be archived on Nektar's
website for 60 days following the event.
Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing
novel therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has completed Phase 3 development as a once- daily, oral tablet for the
treatment of opioid-induced constipation. For naloxegol, an MAA has been
accepted for filing in Europe, and an NDA has been submitted for filing in the
U.S. This agreement also includes NKTR-119, an earlier stage development
program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic molecule for chronic pain conditions, has completed Phase
2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a
novel mu-opioid analgesic molecule in development to treat acute pain is in
Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is
being evaluated in a Phase 3 clinical study (the BEACON study) for the
treatment of metastatic breast cancer and is also in a number of Phase 2
studies. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted
by Bayer Healthcare to treat patients with Gram-negative pneumonia.
Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia^® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS^® for
hepatitis C and Amgen's Neulasta^® for neutropenia. Additional
development-stage products that leverage Nektar's proprietary technology
platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program,
which is in Phase 3 clinical development.
Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate," "intend," "plan,"
"expect," "believe," "should," "may," "will" and similar references to future
periods. Examples of forward-looking statements include, among others, the
value and potential of our technology and research and development pipeline.
Forward-looking statements are neither historical facts nor assurances of
future performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future
plans and strategies, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of our control.
Our actual results may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these
forward-looking statements. Important factors that could cause our actual
results to differ materially from those indicated in the forward-looking
statements include, among others: (i) our drug candidates and those of our
collaboration partners are in various stages of clinical development and the
risk of failure is high and can unexpectedly occur at any stage prior to
regulatory approval for numerous reasons including safety and efficacy
findings even after positive findings in previous preclinical and clinical
studies; (ii) the timing of the commencement or end of clinical trials and the
commercial launch of our drug candidates may be delayed or unsuccessful due to
regulatory delays, slower than anticipated patient enrollment, manufacturing
challenges, changing standards of care, evolving regulatory requirements,
clinical trial design, clinical outcomes, competitive factors, or delay or
failure in ultimately obtaining regulatory approval in one or more important
markets; (iii) acceptance, review and approval decisions for new drug
applications by health authorities is an uncertain and evolving process and
health authorities retain significant discretion at all stages of the
regulatory review and approval decision process; (iv) scientific discovery of
new medical breakthroughs is an inherently uncertain process and the future
success of the application of our technology platform to potential new drug
candidates is therefore highly uncertain and unpredictable and one or more
research and development programs could fail; and (v) certain other important
risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August 9, 2013. Any
forward-looking statement made by us in this press release is based only on
information currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to update any forward-looking
statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
Nektar Investor & Media Inquiries
Jennifer Ruddock/Nektar Therapeutics (415) 482-5585
Susan Noonan/SA Noonan Communications, LLC (212) 966-3650
SOURCE Nektar Therapeutics
Press spacebar to pause and continue. Press esc to stop.